A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] With MK-3475 [Pembrolizumab] Coformulation) in Participants With Relapsed or Refractory Hematological Malignancies
The purpose of the study is to determine the safety and tolerability of
pembrolizumab/vibostolimab (MK-7684A) in hematological malignancies. This study will also
evaluate the overall response rate (ORR), the duration of response (DOR), and disease control
rate (DCR) following administration of pembrolizumab/vibostolimab. In addition, this study
will characterize pharmacokinetic (PK) profile of vibostolimab (MK-7684).
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.